Aclaris Therapeutics (NASDAQ:ACRS) – Research analysts at William Blair boosted their FY2018 earnings per share estimates for shares of Aclaris Therapeutics in a report released on Monday, March 12th, Zacks Investment Research reports. William Blair analyst T. Lugo now expects that the biotechnology company will earn ($3.85) per share for the year, up from their previous forecast of ($4.88). William Blair also issued estimates for Aclaris Therapeutics’ FY2019 earnings at ($2.87) EPS and FY2020 earnings at ($0.65) EPS.
Several other brokerages have also commented on ACRS. BidaskClub upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Zacks Investment Research lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Cantor Fitzgerald set a $50.00 target price on Aclaris Therapeutics and gave the company a “buy” rating in a research report on Friday, December 15th. Leerink Swann cut their target price on Aclaris Therapeutics from $56.00 to $54.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 13th. Finally, Guggenheim initiated coverage on Aclaris Therapeutics in a research report on Thursday, February 8th. They set a “buy” rating and a $53.00 target price on the stock. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $43.50.
Shares of ACRS stock opened at $16.46 on Wednesday. The stock has a market capitalization of $512.35, a PE ratio of -6.58 and a beta of 1.63. Aclaris Therapeutics has a 1-year low of $16.01 and a 1-year high of $33.10.
Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.10. The company had revenue of $1.00 million during the quarter, compared to analyst estimates of $0.80 million.
A number of large investors have recently made changes to their positions in ACRS. Franklin Resources Inc. boosted its holdings in Aclaris Therapeutics by 27.9% in the fourth quarter. Franklin Resources Inc. now owns 2,596,814 shares of the biotechnology company’s stock worth $64,037,000 after acquiring an additional 565,945 shares in the last quarter. BlackRock Inc. boosted its holdings in Aclaris Therapeutics by 28.4% in the fourth quarter. BlackRock Inc. now owns 2,195,028 shares of the biotechnology company’s stock worth $54,129,000 after acquiring an additional 485,146 shares in the last quarter. AXA bought a new position in Aclaris Therapeutics in the fourth quarter worth approximately $6,455,000. Driehaus Capital Management LLC boosted its holdings in Aclaris Therapeutics by 73.8% in the fourth quarter. Driehaus Capital Management LLC now owns 523,428 shares of the biotechnology company’s stock worth $12,908,000 after acquiring an additional 222,254 shares in the last quarter. Finally, Alyeska Investment Group L.P. boosted its holdings in Aclaris Therapeutics by 85.2% in the third quarter. Alyeska Investment Group L.P. now owns 467,884 shares of the biotechnology company’s stock worth $12,076,000 after acquiring an additional 215,201 shares in the last quarter. Institutional investors and hedge funds own 92.19% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “William Blair Comments on Aclaris Therapeutics’ FY2018 Earnings (NASDAQ:ACRS)” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/07/aclaris-therapeutics-inc-forecasted-to-earn-fy2018-earnings-of-3-85-per-share-acrs.html.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.